ProCE Banner Activity

PARP Inhibitor Combinations in Prostate Cancer: Immune Checkpoint Inhibitors and Other Agents

Slideset Download
This downloadable slide set from a live Webinar explores the rationale for combining PARP inhibitors with different types of agents for advanced prostate cancer, including immunotherapy, targeted agents, and radionuclides, incorporating the latest evidence from ASCO GU 2021.

Released: February 19, 2021

Expiration: February 18, 2022

No longer available for credit.

Share

Faculty

Charles Ryan

Charles Ryan, MD

Associate Clinical Professor
Department of Medicine Hematology/Oncology
University of California, San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.

Pfizer TEXT Only

Faculty Disclosure

Primary Author

Charles Ryan, MD

Associate Clinical Professor
Department of Medicine Hematology/Oncology
University of California, San Francisco
San Francisco, California